 Member since May '08
Working languages: Catalan to Spanish
Spanish to Catalan
English to Catalan
English to Spanish |
Availability today:  | November 2009 |  | | S | M | T | W | T | F | S | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | | 8 | 9 | 10 | 11 | 12 | 13 | 14 | | 15 | 16 | 17 | 18 | 19 | 20 | 21 | | 22 | 23 | 24 | 25 | 26 | 27 | 28 | | 29 | 30 | 31 | | | | | |
|  Marta Cervera
www.martacervera.com
Tarrasa, Cataluña Local time: 06:38 CET (GMT+1)
Native in: Catalan  , Spanish | | |
Accurate translations always on time | Freelancer,  Verified member | | Translation, Editing/proofreading, Transcription, Desktop publishing | | Specializes in: | | Medical: Pharmaceuticals | Medical: Dentistry | | Medical: Health Care | Medical (general) | | Computers (general) | IT (Information Technology) |
| Also works in: | | Medical: Instruments | Medical: Cardiology | | Biology (-tech,-chem,micro-) | Chemistry; Chem Sci/Eng | | General / Conversation / Greetings / Letters | Psychology | | History | Advertising / Public Relations |
More Less | Catalan to Spanish - Rates: 0.05 - 0.08 EUR per word / 30 - 35 EUR per hour
Spanish to Catalan - Rates: 0.05 - 0.08 EUR per word / 30 - 35 EUR per hour
English to Catalan - Rates: 0.07 - 0.10 EUR per word / 30 - 35 EUR per hour
English to Spanish - Rates: 0.07 - 0.10 EUR per word / 30 - 35 EUR per hour
| | Questions answered: 82, Questions asked: 0 Easy / 7 PRO, PRO-level points: 76 | Sample translations submitted: 1| English to Spanish: Abstract - Pharmaceutical | Source text - English
ABSTRACT. Microalbuminuria and hypertension are risk factors for diabetic nephropathy in Type 2 diabetic patients. Recent data suggest that blockade of the renin-angiotensin system slows the progression of diabetic nephropathy; in contrast, the results on the renoprotective effect of calcium channel antagonists are conflicting. We evaluated the effectiveness of lercanidipine, in comparison with ramipril, on the reduction in albumin excretion rate (AER) and blood pressure in mild-to-moderate hypertensive patients with Type 2 diabetes and persistent microalbuminuria. A total of 277 patients were enrolled in a multicentric, randomized, double-blind, active-controlled, parallel-group trial; 180 were randomized to receive 10-20 mg/day of lercanidipine or 5-10 mg/day of ramipril and followed up for 9-12 months. The primary outcome was the change in AER from baseline. After 9-12 months of follow-up, a reduction in AER of –17.4±65 μg/min (p<0.05) and –19.7±52.5 (p<0.05) in the lercanidipine and ramipril group, respectively, was observed, without differences between the groups. A significant
reduction in systolic and diastolic blood pressure was observed in both the lercanidipine and ramipril-based treatment groups (p<0.0001 for both). This study demonstrated that treatment with lercanidipine 10-20 mg/day do not worsen albuminuria in microalbuminuric Type 2 diabetic patients with hypertension. Indeed, both lercanidipine and ramipril treatments resulted in a significant reduction in AER without a statistically significant difference between the two groups.
| Translation - Spanish
RESUMEN. La microalbuminuria y la hipertensión son factores de riesgo para la nefropatía diabética en pacientes con diabetes tipo 2. Los datos recientes sugieren que el bloqueo del sistema renina-angiotensina ralentiza la progresión de la neuropatía diabética; por lo contrario, los resultados sobre el efecto renoprotector de los antagonistas del canal de calcio son contradictorios. Hemos evaluado la efectividad de la lercanidipina en comparación con el ramipril sobre la reducción de la tasa de excreción de albúmina (TEA) y la tensión arterial en pacientes con hipertensión leve a moderada, diabetes de tipo 2 y oligoalbuminuria persistente. Un total de 277 pacientes participaron en un ensayo multicéntrico, aleatorizado, en doble ciego y activamente controlado en grupos paralelos; 180 recibieron de forma aleatoria 10-20 mg/día de lercanidipina o 5-10 mg/día de ramipril y se les realizó un seguimiento durante 9-12 meses. El resultado principal fue el cambio en la TEA respecto de los valores basales. Después de 9-12 meses de seguimiento, se observó una reducción en la TEA de -17,4±65 μg/min (p<0,05) y -19,7±52,5 (p<0,05) en los grupos de lercanidipina y ramipril, respectivamente, sin diferencias entre los grupos. Se observó una reducción significativa de la tensión arterial sistólica y diastólica tanto en el grupo de tratamiento de lercanidipina como en el de ramipril (p<0,0001 para ambos). Este estudio demostró que el tratamiento con lercanidipina 10-20 mg/día no empeora la albuminuria en pacientes oligoalbuminúricos con diabetes del tipo 2 e hipertensión. Efectivamente, ambos tratamientos de lercanidipina y ramipril tuvieron como resultado una reducción significativa de la TEA sin una diferencia estadísticamente significativa entre ambos grupos. |
More Less | | BA-Autonomous University of Barcelona (Spain) | | Years of translation experience: 6. Registered at ProZ.com: Apr 2002. Became a member: May 2008. | | N/A | English to Spanish (Spain, UAB (Autonomous University of Barcelona))
English to Catalan (Spain, UAB (Autonomous University of Barcelona))
Catalan to Spanish (Spain, UAB (Autonomous University of Barcelona))
Spanish to Catalan (Spain, UAB (Autonomous University of Barcelona))
| | N/A | | Across, Adobe Acrobat, Adobe Illustrator, Adobe Photoshop, FrameMaker, Indesign, Microsoft Excel, Microsoft Word, WebWorks Publisher, Powerpoint, SDL TRADOS, STAR Transit | | http://www.martacervera.com | | English (PDF), Spanish (PDF), Catalan (PDF) | | Marta Cervera endorses ProZ.com's Professional Guidelines. | | Keywords: medicina, medical, odontología, odontology, dental, IT, informática, informatics, computer, computación, technical writing, redacción técnica.
Profile last updated
Oct 6 |
The translation workplace 
Expertise